Hongchang International Revenue Soars 161% on Acquisitions, Profit Rebounds

TL;DR

**HCIL's revenue exploded and they're finally profitable, but watch that cash burn and rising receivables – it's a high-risk, high-reward play.**

AI Summary

Hongchang International Co., Ltd (HCIL) reported a significant increase in revenue and net income for the three and six months ended September 30, 2025. Revenue for the three months jumped to $3,470,693 from $820,608 in the prior year, a 322.9% increase. Net income for the same period was $198,247, a substantial turnaround from a net loss of $44,771 in 2024. For the six months ended September 30, 2025, revenue surged to $7,314,841 from $2,802,506, marking a 161.0% increase, and net income reached $698,189, reversing a $66,451 loss. Key business changes include the acquisition of a 51% equity interest in Pucheng Green Health Food Co., Ltd. on January 1, 2025, expanding into livestock slaughtering. The company also saw a decrease in cash and cash equivalents from $493,201 to $32,479, and a significant increase in accounts receivable from $2,278,878 to $3,544,467. Risks include reliance on estimates for financial reporting and foreign currency translation differences, which significantly impacted comprehensive income.

Why It Matters

This filing reveals HCIL's aggressive expansion into meat processing and food trade, evidenced by the Pucheng Green Health Food acquisition, which could reshape its competitive landscape against established players. The dramatic revenue growth and return to profitability signal potential for investors, but the substantial increase in accounts receivable and decrease in cash warrant close scrutiny regarding liquidity and operational efficiency. Employees might see increased job security and growth opportunities with the expanding business lines. For customers, this could mean a broader range of food products from a more integrated supply chain. The broader market will watch if HCIL can sustain this growth and successfully integrate its new ventures.

Risk Assessment

Risk Level: high — The company experienced a significant net decrease in cash of $456,448 for the six months ended September 30, 2025, and cash and cash equivalents plummeted from $493,201 to $32,479. Additionally, accounts receivable increased by over $1.2 million to $3,544,467, indicating potential collection challenges or aggressive credit terms, which could strain working capital despite revenue growth.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence on HCIL's cash flow management and accounts receivable collection practices. While revenue growth is impressive, the rapid decline in cash and significant increase in receivables suggest potential liquidity issues that could undermine future profitability. Consider waiting for more consistent positive cash flow from operations before investing.

Financial Highlights

debt To Equity

0.45

revenue

$7.31M

operating Margin

16.7%

total Assets

$61.74M

total Debt

$19.14M

net Income

$698.19K

eps

$0.00

gross Margin

16.7%

cash Position

$32.48K

revenue Growth

+161.0%

Revenue Breakdown

Key Numbers

• $7.31M — Revenue (Increased 161.0% for the six months ended September 30, 2025, from $2.80M in 2024.)
• $698.19K — Net Income (Turned from a loss of $66.45K in 2024 to a profit for the six months ended September 30, 2025.)
• $32.48K — Cash and Cash Equivalents (Decreased significantly from $493.20K as of March 31, 2025, indicating cash burn.)
• $3.54M — Accounts Receivable (Increased from $2.28M as of March 31, 2025, suggesting potential collection challenges.)
• 51% — Equity Interest (Acquired in Pucheng Green Health Food Co., Ltd. on January 1, 2025, expanding business operations.)
• $456.45K — Net Decrease in Cash (For the six months ended September 30, 2025, highlighting liquidity concerns.)
• $1.22M — Change in Accounts Receivable (Negative impact on cash flow from operating activities for the six months ended September 30, 2025.)

Key Players & Entities

• Hongchang International Co., Ltd (company) — Registrant and holding company
• Pucheng Green Health Food Co., Ltd. (company) — Acquired subsidiary, 51% equity interest
• Mr. Zengqiang Lin (person) — Director and controlling stockholder
• Ms. Zhenzhu Lin (person) — Controlling stockholder and sister of Mr. Zengqiang Lin
• Hongchang BVI (company) — Wholly owned subsidiary after merger
• SEC (regulator) — U.S. Securities and Exchange Commission
• $3,470,693 (dollar_amount) — Revenue for three months ended September 30, 2025
• $198,247 (dollar_amount) — Net income for three months ended September 30, 2025
• $7,314,841 (dollar_amount) — Revenue for six months ended September 30, 2025
• $698,189 (dollar_amount) — Net income for six months ended September 30, 2025

FAQ

Risk Factors

• Cash Position Deterioration [high — financial]: Cash and cash equivalents decreased from $493,201 to $32,479 for the six months ended September 30, 2025. This significant reduction, a net decrease of $456,451, indicates substantial cash burn and raises concerns about the company's short-term liquidity.
• Accounts Receivable Growth [medium — financial]: Accounts receivable increased from $2,278,878 to $3,544,467 as of September 30, 2025. This $1.22M increase, while potentially linked to revenue growth, could signal potential collection challenges and negatively impact operating cash flow.
• Integration of New Business [medium — operational]: The acquisition of 51% equity in Pucheng Green Health Food Co., Ltd. introduces new operational complexities in the livestock slaughtering industry. Successful integration is crucial for realizing the expected synergies and avoiding operational disruptions.
• Reliance on Estimates [low — financial]: The financial statements rely on estimates for financial reporting. Changes in these estimates, particularly concerning revenue recognition, inventory valuation, or asset impairments, could materially affect reported results.
• Foreign Currency Translation [low — financial]: Foreign currency translation differences significantly impacted comprehensive income, resulting in a change from a negative $131,400 to a positive $693,320 in accumulated other comprehensive income. This volatility exposes the company to exchange rate fluctuations.

Industry Context

Hongchang International operates in diverse sectors, including potentially food processing and related industries following its recent acquisition. The livestock slaughtering industry is characterized by supply chain complexities, regulatory oversight, and fluctuating commodity prices. Growth in this sector is often tied to consumer demand for protein and efficiency in processing.

Regulatory Implications

The company's operations, particularly in the newly acquired livestock slaughtering business, are subject to stringent food safety and environmental regulations. Compliance with these regulations is critical to avoid penalties and maintain operational continuity. Foreign currency translation also implies operations or significant transactions in foreign markets, necessitating adherence to international accounting standards.

What Investors Should Do

1. Monitor cash flow and liquidity closely.
2. Analyze the drivers of accounts receivable growth.
3. Evaluate the performance and integration of Pucheng Green Health Food Co., Ltd.
4. Assess the impact of foreign currency fluctuations.

Key Dates

• 2025-01-01: Acquisition of 51% equity interest in Pucheng Green Health Food Co., Ltd. — Marks a significant diversification into the livestock slaughtering industry, aiming to expand revenue streams and market reach.
• 2025-09-30: End of the second fiscal quarter and six-month period. — Reporting period showing substantial revenue and net income growth, alongside a significant decrease in cash and increase in accounts receivable.

Glossary

Accumulated other comprehensive income

Includes unrealized gains and losses that are not reported in net income but affect equity. For HCIL, this includes foreign currency translation adjustments. (Shows a significant positive swing, primarily due to foreign currency translation, impacting overall equity.)

Non-controlling interests

Represents the portion of equity in a subsidiary that is not owned by the parent company. For HCIL, this increased from $815,055 to $1,166,739, likely due to the consolidation of the acquired subsidiary. (Indicates the growing influence of the acquired subsidiary on the consolidated financial statements.)

Equity-method investments

An accounting method where an investment in another company is recorded at cost and adjusted for the investor's share of the investee's net income or loss. (This line item decreased from $527,684 to $0, suggesting the company may have fully acquired or divested from these investments, or they were consolidated into the Pucheng acquisition.)

Deferred offering cost

Costs incurred in connection with a planned offering of securities that have not yet been issued. (A new $80,000 entry suggests potential future equity financing activities.)

Year-Over-Year Comparison

Compared to the prior year, Hongchang International has demonstrated exceptional revenue growth, with a 161.0% increase for the six months ended September 30, 2025, reaching $7.31M. This surge has also led to a significant turnaround in profitability, moving from a net loss of $66,451 to a net income of $698,189. However, this growth has come at the cost of liquidity, as cash and cash equivalents have plummeted from $493,201 to $32,479, and accounts receivable have risen substantially. New risks related to the integration of the acquired subsidiary and ongoing foreign currency impacts are also present.

Key Financial Figures

• $ — functional currency of the Company is US$, and the functional currency of the Com

Filing Documents

• ea0264488-10q_hongchang.htm (10-Q) — 776KB
• ea026448801ex10-1_hongchang.htm (EX-10.1) — 228KB
• ea026448801ex31-1_hongchang.htm (EX-31.1) — 10KB
• ea026448801ex31-2_hongchang.htm (EX-31.2) — 10KB
• ea026448801ex32-1_hongchang.htm (EX-32.1) — 5KB
• ea026448801ex32-2_hongchang.htm (EX-32.2) — 5KB
• ex10-1_001.jpg (GRAPHIC) — 2KB
• 0001213900-25-109977.txt ( ) — 6231KB
• hcil-20250930.xsd (EX-101.SCH) — 68KB
• hcil-20250930_cal.xml (EX-101.CAL) — 57KB
• hcil-20250930_def.xml (EX-101.DEF) — 288KB
• hcil-20250930_lab.xml (EX-101.LAB) — 513KB
• hcil-20250930_pre.xml (EX-101.PRE) — 307KB
• ea0264488-10q_hongchang_htm.xml (XML) — 695KB

FINANCIAL

Part I. FINANCIAL INFORMATION 1 Item 1.

Financial Statements

Financial Statements 1 Condensed Consolidated Balance Sheets (Unaudited) 1 Condensed Consolidated 2 Condensed Consolidated 3 Condensed Consolidated 4 Notes to Condensed Consolidated

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3. Quantitative and Qualitative Disclosures about Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 36

OTHER

Part II. OTHER INFORMATION 37 Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3. Defaults Upon Senior Securities 37 Item 4. Mine Safety Disclosures 37 Item 5. Other Information 37 Item 6. Exhibits 38 i

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS This quarterly report on Form 10-Q (this "Report"), financial statements, and notes to financial statements contain forward-looking statements that discuss, among other things, future expectations and projections regarding future developments, operations, and financial conditions. Forward-looking statements may appear throughout this Report and other documents we file with the U.S. Securities and Exchange Commission (the "SEC"), including without limitation, the following section: Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Report.

Forward-looking statements generally can be identified

Forward-looking statements generally can be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "will be," "will continue," "may," "could," "will likely result," and similar expressions. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause our actual results to differ materially from those reflected in the forward-looking statements. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. ii

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Hongchang International Co., Ltd Condensed Consolidated Balance Sheets As of September 30, 2025 March 31, 2025 (unaudited) US$ US$ ASSETS: Current assets: Cash and cash equivalents 32,479 493,201 Restricted cash 221,974 217,700 Accounts receivable 3,544,467 2,278,878 Other receivables 955,541 74,693 Inventories, net 39,430 36,206 Advances to suppliers 1,212 175,389 Other current assets 614,299 757,833 Total current assets 5,409,402 4,033,900 Non-current assets: Property and equipment, net 27,446,545 27,139,534 Construction-in-progress 17,892,153 16,832,470 Intangible assets, net - - Land use rights, net 4,030,601 3,998,567 Equity-method investments - 527,684 Deferred offering cost 80,000 - Other non-current assets 6,880,429 7,005,938 Total non-current assets 56,329,728 55,504,193 Total assets 61,739,130 59,538,093 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Long-term loans-current portion 293,563 378,026 Accounts payable 2,434,282 2,263,805 Accounts payable-construction in progress 16,930 13,639 Amounts due to related parties-current portion 3,409,988 2,950,075 Advances from customers 261 256 Accrued expenses and other liabilities 643,311 841,789 Total current liabilities 6,798,335 6,447,590 Non-current liabilities Deferred subsidies 1,956,423 1,935,462 Long term loans 6,797,394 6,556,390 Amounts due to related parties 3,581,556 3,513,737 Deferred tax liabilities 3,269 7,675 Total non-current liabilities 12,338,642 12,013,264 Total liabilities 19,136,977 18,460,854 Commitments and contingencies Stockholders' equity: Common stock (US$ 0.001 par value; 2,000,000,000 shares authorized; 518,831,367 and 518,831,367 issued and outstanding as of September 30, 2025 and March 31, 2025, respectively) 518,831 518,831 Additional paid-in capital 39,905,228 39,905,228 Statutory

View Full Filing

View this 10-Q filing on SEC EDGAR